Reducing fracture risk in men on androgen deprivation therapy

被引:0
作者
Vahakn B. Shahinian
机构
[1] University of Michigan,
[2] 102 Observatory Road,undefined
[3] 208 Simpson Memorial Institute,undefined
来源
Nature Reviews Urology | 2011年 / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Androgen deprivation therapy (ADT) is well established as a cause of osteoporosis and increased fracture risk. A study has shown that toremifene reduces fracture risk in men receiving ADT for prostate cancer. The study has substantial limitations, however, and the management of bone disease in these patients remains a challenge.
引用
收藏
页码:9 / 10
页数:1
相关论文
共 17 条
  • [1] Shahinian VB(2005)Risk of fracture after androgen deprivation for prostate cancer N. Engl. J. Med. 352 154-164
  • [2] Kuo YF(2007)Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann. Intern. Med. 146 416-424
  • [3] Freeman JL(2003)Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J. Urol. 169 2008-2012
  • [4] Goodwin JS(2010)Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer J. Urol. 184 1316-1321
  • [5] Greenspan SL(2006)Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J. Clin. Oncol. 24 4448-4456
  • [6] Nelson JB(2004)Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation Obstet. Gynecol. 104 837-844
  • [7] Trump DL(2009)Denosumab in men receiving androgen-deprivation therapy for prostate cancer N. Engl. J. Med. 361 745-755
  • [8] Resnick NM(2010)Intermittent androgen suppression for prostate cancer Nat. Rev. Urol. 7 552-560
  • [9] Smith MR(undefined)undefined undefined undefined undefined-undefined
  • [10] Smith MR(undefined)undefined undefined undefined undefined-undefined